Allergan’s Preservation-Free Bimatoprost-Timolol Medication Recieves Marketing Extention in Europe

Sunday, September 8th, 2013

Allergan recently announced that the European Medicines Agency (EMA) extended its marketing authoriziation for one of its medications- Ganfort. Ganfort is a combination medication with bimatoprost and timolol. It is an ophthalmic solution with preservation-free formulation, packaged in single-dose containers. The marketing authorization covers all European Union (EU) countries. Ganfort is indicated for reducing intraocular […]

Bimatoprost and Timolol Patent Revoked by India

Wednesday, August 14th, 2013

In a recent press announcement, Indian pharmaceutical company Ajanta Pharma said that it was successful in revoking the patents held by Allergan, Inc. on two drugs- bimatoprost and timolol- in India. In a press release statement, the company stated that it has, “emerged successful in revoking composition patents of Allergan.” The Indian pharmaceutical company had […]

Bimatoprost Lasts Longer than Latanoprost

Saturday, June 29th, 2013

Bimatoprost and Latanoprost are both ophthalmic medications, and a study conducted in the United States showed that the former lasted longer without degradation in a patient-use setting. The study was done by John G. Walt from the Global Health Outcomes Strategy & Research, Allergan, Inc. The stability of ophthalmic drugs stored in multi-dose containers is […]